<DOC>
	<DOCNO>NCT02893540</DOCNO>
	<brief_summary>The optimum regimen maintenance treatment first-line chemotherapy patient metastatic colorectal cancer ( mCRC ) unknown . This study design determine efficacy safety maintenance treatment capecitabine metronomic chemotherapy versus conventional chemotherapy .</brief_summary>
	<brief_title>Metronomic Versus Conventional Chemotherapy Maintenance Treatment mCRC</brief_title>
	<detailed_description>In Prospective , open-label , randomise control trial , investigator recruit 250 mCRC patient finish 18 24 week first-line chemotherapy disease evaluation SD , PR CR . Then , patient randomise two group . The experimental group , capecitabine metronomic chemotherapy versus capecitabine conventional chemotherapy control group . These treatment regimen continue progression , death , unacceptable adverse event . The primary endpoint progression-free survival ( PFS ) . Secondary endpoint overall survival ( OS ) , quality life ( QOL ) toxic effect .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histological proof colorectal cancer ( case single metastasis , histological cytological proof lesion obtain ) ; Distant metastasis ( patient local recurrence eligible ) ; Unidimensionally measurable disease ( &gt; 1 cm spiral CT scan &gt; 2 cm chest Xray ; liver ultrasound allow ) . Serum CEA may use parameter disease evaluation ; In case previous radiotherapy , least one measurable lesion locate outside irradiated field . Prior adjuvant treatment stage II/III colorectal cancer end within 6 month start induction treatment ; Any prior adjuvant treatment resection distant metastasis ; Previous systemic treatment advance disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>